- Global Pharma News & Resources

Senior Business Executives Join Life Biosciences ‘Dream Team’

Life Biosciences Inc. announced today the appointment of three senior executives who bring decades of business expertise to key positions at the pioneering company. Brian Malone is named chief financial officer; Ivan Kaplan is corporate counsel, and Nick Ventresca is chief technology officer.

Life Biosciences is the first and largest company to address age-related decline (ARD) as a systemic breakdown of the body, rather than a series of isolated events and conditions. These three senior business leaders will support the financial, legal and technology expansion of the company, as well as of the Life Biosciences’ Daughter companies, as they pursue their independent and collaborative research into the eight pathways of age-related decline.

“We are delighted to bring these outstanding corporate talents to our business,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their individual and collective expertise ensures we have uniquely well-qualified senior professionals leading our company as it grows. They are invaluable contributors to our mission.”

Brian Malone, chief financial officer, brings more than 35 years of experience in financial services with investment firms in Ireland, London and Boston. Malone was the chief financial officer of Longwood Fund Management, also serving as the first CFO/COO of many of the companies that Longwood incubated. Most recently, he was the senior vice president of finance at Axial Biotherapeutics Inc., responsible for finance, operations and information technology.

Corporate counsel Ivan Kaplan is a practicing corporate governance and securities attorney. Previously, he was an associate at Wilson Sonsini Goodrich & Rosati, counseling clients on matters of corporate transactions and general corporate governance.

Nick Ventresca, chief technology officer, is responsible for the creation of Life Biosciences’ data and technology platform. He comes to the company after more than 20 years in information technology for large multinational organizations, mid-sized biopharmas and start-up biotechs. He has broad international expertise implementing innovative scientific and patient-centric technology. Previously, he served as chief information officer for high profile organizations within the pharmaceutical and healthcare industries. Most recently, he developed strategic IT solutions for late-stage biotechs now commercializing.

Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 25,000 square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company’s Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals.

For more information on Life Biosciences, please visit

View source version on

Editor Details

Last Updated: 23-Oct-2018